Teva fits a preference for low-valuation stocks as rates rise, and its chart points to another leg higher. It looks to be breaking out of an ascending triangle toward the $45 area. x.com 

Teva is a quality, fairly priced grower in a world of uncertainty and bubbles, and strong results sent the shares gapping higher. It faces some diagonal resistance but should get above $40 soon. x.com